EMERYVILLE, Calif., Oct. 15, 2010 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces that it will deliver two poster presentations on its compounds at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA). The conference will take place October 21-24, 2010, at the Vancouver Convention and Exhibition Centre in Vancouver, British Columbia, Canada.
The presentations will include new data from clinical and preclinical studies of NovaBay's lead Aganocide® compound.
Ron Najafi, chairman and CEO of NovaBay, said, "These presentations illustrate NovaBay's ongoing efforts to address the growing global crisis of antibiotic resistance by developing and commercializing an extensive pipeline of first-in-class, non-antibiotic anti-infective compounds that are designed to treat infections without the use of antibiotics."
NovaBay's pipeline of Aganocide compounds is being studied in numerous preclinical and clinical programs. Clinical programs using the company's lead Aganocide drug candidate are under way for the treatment of impetigo, a highly contagious skin infection, for the prevention of urinary catheter encrustation and blockage and for the treatment of conjunctivitis or pink eye.
Poster session details are as follows:
In vitro Evaluation of Antifungal Activity of NVC-422 Using a Novel Cadaver Nail Model
A Pilot Study to Evaluate the Safety and Efficacy of NVC-422 Topical Gel in Impetigo, Including MRSA
About IDSA 2010
The meeting brings together physicians, scientists, and other health care professionals involved in research, patient care, public health, disease prevention, and education in the field of infectious diseases. This meeting provides three and a half days of broad continuing educational courses and comprehensive educational experiences in the major facets of infectious diseases: pathophysiology, diagnosis, treatment, and prevention. The courses combine expert reviews of the traditional field of infectious diseases with emphasis on the most contemporary trends, including emerging infections, new diagnostics, vaccines, and therapeutics.
About Aganocides
NovaBay's Aganocide® compounds are novel, synthetic N-chlorinated antimicrobial molecules specifically designed and developed to mimic the body's natural defense against infection. The Aganocide compounds maintain biological activities while demonstrating improved stability over the naturally occurring N-chlorinated antimicrobial molecules. In preclinical testing, NovaBay's Aganocide compounds have been shown to be highly effective against bacteria, including some multi-drug resistant strains (such as MRSA), viruses and fungi. NovaBay's Aganocide compounds have the potential to deliver the same or better efficacy than antibiotics, and to address the growing problem of antibiotic resistance by employing a novel mechanism of action.
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary and patented Aganocide compounds, which are novel, synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white blood cells. NovaBay's Aganocide compounds are being developed to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay has internal development programs aimed at addressing hospital and respiratory infections. The company has a license and research collaboration agreement with Alcon, Inc. for use of its Aganocide compounds to treat eye, ear and sinus infections as well as for contact lens care. NovaBay has also entered into an agreement with Galderma S.A. to develop and commercialize Aganocide compounds in impetigo and other dermatological indications. For more information on NovaBay, visit: .
Cautionary Information Regarding Forward-Looking Statements
The statements in this press release of NovaBay's expectations and the potential regarding its Aganocide compounds are forward-looking statements. Actual results may differ materially due to a number of risks and uncertainties, including: results in preclinical and other studies may differ from results obtained in clinical trials; unexpected results may be obtained in further studies due to the inherent uncertainty in the development of NovaBay's compounds; and the inherent uncertainty of obtaining regulatory approvals may prevent NovaBay from being able to bring its potential products to market. Other risks relating to NovaBay and its Aganocide compounds, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's Quarterly Report on Form 10-Q for the period ended June 30, 2010, under the caption "Risk Factors" in Item 1A of Part II of that report, filed with the Securities and Exchange Commission on August 12, 2010. The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
CONTACT: NovaBay Pharmaceuticals, Inc. Investors: Thomas J. Paulson, Chief Financial Officer 510-899-8809 tpaulson@novabaypharma.com The Investor Relations Group Investor Relations: Adam Holdsworth 212-825-3210 adam@investorrelationsgroup.com Public Relations: Laura Colontrelle 212-825-3210 laura@investorrelationsgroup.com